Who makes the decisions regarding the benefit status of medications listed in the Nova Scotia Formulary?
The Atlantic Expert Advisory Committee and the Canadian Expert Drug Advisory Committee make recommendations on the benefit status of drugs and supplies to the Department of Health and Wellness. These committees include medical specialists, family practitioners, and pharmacists. They consult experts in specialty areas as required. The benefit evaluation process typically begins when a manufacturer requests to have a product evaluated for benefits status. Guidelines list the information that the manufacturer must submit. Submission requirements for the Atlantic Common Drug Review process are available on this website and submission requirements for the Canadian Common Drug Review process are available on the Canadian Agency for Drugs and Technologies in Health website. Clinical studies are reviewed extensively. Coverage for new products is not available until this process is completed and the drug has been added to the benefit list. A drug may be added as a full benefit, denied any benef
Related Questions
- What is an exception status drug and do you have a process to consider paying for drugs not listed as a benefit in the Nova Scotia Formulary?
- I came to the United States in F-2 status but changed status to F-1 after being here for a year. Can I claim a treaty benefit?
- I am a Survivor Benefit Plan (SBP) annuitant. How do I change my federal tax status, or FITW?